Caredx (CDNA) closed at $71.92 on November 19, 2026, down 3.4% from the previous close, on volume of 836,376 shares (30-day average 1,208,465).
Data as of November 19, 2026.
19-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Put Spread | 19-Feb-2765 : 80 P | 1,048 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 18, 2026. See the largest for 5, 30, 60 and 90 days
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 6-Nov 4:05 PM ET)
CareDx Announces Third KOAR Analysis Published in Transplantation
Business Wire (Tue, 3-Nov 7:05 AM ET)
CareDx soars as Q3 revenue hits $139M and 2026 guidance jumps to $520M–$530M
Market Chameleon (Fri, 30-Oct 6:02 AM ET)
CareDx Announces Third Quarter 2026 Financial Results
Business Wire (Thu, 29-Oct 4:01 PM ET)
Business Wire (Thu, 22-Oct 7:05 AM ET)
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
Business Wire (Thu, 15-Oct 4:01 PM ET)
CareDx Grants Nearly 16,000 RSUs to Executive Advisor as Part of Strategic Leadership Expansion
Market Chameleon (Mon, 3-Aug 4:38 AM ET)
Market Chameleon (Thu, 16-Jul 4:32 AM ET)
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Caredx trades on the NASDAQ stock market under the symbol CDNA.
As of November 19, 2026, CDNA stock price declined to $71.92 with 836,376 million shares trading.
CDNA has a beta of 0.54, meaning it tends to be less sensitive to market movements. CDNA has a correlation of 0.01 to the broad based SPY ETF.
CDNA has a market cap of $3.78 billion. This is considered a Mid Cap stock.
Last quarter Caredx reported $139 million in Revenue and $.70 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.48.
In the last 3 years, CDNA traded as high as $90.87 and as low as $7.42.
The top ETF exchange traded funds that CDNA belongs to (by Net Assets): VTI, XBI, IWM, ARKG, VXF.
CDNA has outperformed the market in the last year with a return of +356.3%, while the SPY ETF gained +9.6%. In the last 3 month period, CDNA beat the market returning +55.7%, while SPY returned -6.5%. However, in the most recent 2 weeks CDNA has underperformed the stock market by returning -16.2%, while SPY returned -6.6%.
CDNA support price is $71.55 and resistance is $77.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDNA shares will trade within this expected range on the day.